Phase 1 Capabilities
Nine Phase 1 capable sites in 14 locations in the United States and Canada with 23 Principal Investigators
Collectively conducted 55 Phase 1 trials - 21 were first-in human trials
Overnight capabilities in 8 locations with 107 beds combined. Facilities range from 4,000 to 17,000 SF
On-site pharmacies at 6 sites; PBMC capabilities at 5 sites
Over 2.8 million patients in collective databases; diversity recruitment in Hispanic, Asian, and Black communities
Phase 1 Therapeutics
Neurology
NASH Capabilities
Gynecology
Men’s Health
Endocrinology
Gerontology
Cannabis & Psychedelics
Pain Management
Smoking Cessation
Psychiatry
Ophthalmology
Devices / Diagnostics
Nephrology
Vaccine Capabilities
Cardiology
Pediatrics
Rheumatology
Podiatry
Pulmonology
Oncology
Nutrition
Urology
Gastroenterology
Dermatology Capabilities
COVID- 19 Capabilities
Immunology
Hematology
Phase 1 Testing / Equipment
- Biosafety Cabinets (Class II A2)
- Biosafety Cabinets (Class II A2)
- Crash Carts, Defibrillators, ECGs
- Echocardiograms, X-rays, MRIs
- FibroScans®
- Food Effects
- Glucose and Lactate Analyzer
- Glucose Clamping
- Infusion Pumps
- Insulin Challenge
- Laminar Fume Hoods (Sterile)
- Nerve Conduction Testing
- Patient Monitoring Devices
- PBMC Processing
- PK/PD Capabilities
- Point-of-Care Blood Analyzers
- RT-PCR Machines
- Sleep Labs
- Telemetry Machines
